September 2019
Core topics in this month’s edition include:
- Invokana (canagliflozin) - new indication
- NovoLog (insulin aspart), NovoLog Mix (insulin aspart protamine/insulin aspart) - new authorized brand alternatives
- Ranitidine - safety update and drug recall
- Rybelsus (semaglutide) - new drug approval
Top